APPLICATION OF AMPHOTERIC SURFACE-ACTIVE SUBSTANCES FOR THE PREVENTION AND TREATMENT OF PATHOGENIC VAGINAL VAGINAL BIOFILMS IN VAGINAL INFECTIONS

摘要

1. Amphoteric surfactant for use in the prevention and / or treatment of vaginal infections. 2. The amphoteric surfactant according to claim 1, which is amphoacetate, amphodiacetate, amphopropionate, amphodipropionate, hydroxysultaine or any mixtures thereof. 3. The amphoteric surfactant according to claim 1 and / or 2, which is CC-alkylamphoacetate, preferably cocoamphoacetate or lauroamphoacetate, more preferably sodium cocoamphoacetate or sodium lauroamphoacetate, CC-alkylamphopropionate, preferably cocoamphopropionate, more preferably cocoamphopropionate, preferably alkyl cocamide cocoamidopropylhydroxysultaine, or CC-amphodiacetate, preferably cocoamphodiacetate, more preferably sodium cocoamphodiacetate. 4. An amphoteric surfactant according to claim 1, wherein the vaginal infection is characterized by the presence of a (pathogenic) vaginal biofilm. The amphoteric surfactant according to claim 1, wherein the vaginal infection is vulvovaginal candidiasis or bacterial vaginitis. The amphoteric surfactant according to claim 4 and / or 5, where this vaginal biofilm is caused by Candida albicans and Candida spec and / or Gardnerella vaginalis, Atopobium vaginae, Mobiluncus spp., Prevotella spp. and Mykoplasma hominis. 7. The amphoteric surfactant according to claim 1, wherein the amphoteric surfactant is administered in an amount of 0.01-500 mg per dose, preferably 0.1-250 mg per dose, more preferably 1-100 mg per dose. The amphoteric surfactant according to claim 1, wherein the amphoteric surfactant is administered once a day to two times a week. Amphoteric surfactant according to claim 1, where it is an amphoteric surfactant